PerkinElmer Stock Price, News & Analysis (NYSE:PKI)

PerkinElmer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PKI."

PerkinElmer declared a quarterly dividend on Thursday, July 25th. Investors of record on Friday, October 18th will be paid a dividend of $0.07 per share on Friday, November 8th. This represents a $0.28 annualized dividend and a yield of 0.34%. The ex-dividend date is Thursday, October 17th. View PerkinElmer's Dividend History.

PerkinElmer, Inc. (NYSE:PKI) issued its earnings results on Monday, July, 29th. The medical research company reported $1.00 earnings per share for the quarter, missing the Zacks' consensus estimate of $1.01 by $0.01. The medical research company earned $722.50 million during the quarter, compared to analyst estimates of $729.10 million. PerkinElmer had a return on equity of 16.07% and a net margin of 9.01%. PerkinElmer's quarterly revenue was up 2.7% compared to the same quarter last year. During the same period in the prior year, the company earned $0.91 earnings per share. View PerkinElmer's Earnings History.

PerkinElmer is scheduled to release their next quarterly earnings announcement on Wednesday, October 30th 2019. View Earnings Estimates for PerkinElmer.

PerkinElmer will be holding an earnings conference call on Wednesday, October 30th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

PerkinElmer updated its FY19 earnings guidance on Monday, July, 29th. The company provided earnings per share guidance of $4.02-4.07 for the period, compared to the Thomson Reuters consensus estimate of $4.05.

13 analysts have issued 12-month target prices for PerkinElmer's shares. Their predictions range from $41.00 to $115.00. On average, they anticipate PerkinElmer's stock price to reach $77.68 in the next year. This suggests that the stock has a possible downside of 5.5%. View Analyst Price Targets for PerkinElmer.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PerkinElmer in the last year. There are currently 8 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for PerkinElmer.

News headlines about PKI stock have trended very negative recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. PerkinElmer earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave media stories about the medical research company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for PerkinElmer.

PerkinElmer saw a increase in short interest in September. As of September 30th, there was short interest totalling 5,070,000 shares, an increase of 6.5% from the August 30th total of 4,760,000 shares. Based on an average daily volume of 687,000 shares, the short-interest ratio is presently 7.4 days. Currently, 4.6% of the company's stock are sold short. View PerkinElmer's Current Options Chain.

Some companies that are related to PerkinElmer include Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Bio-Rad Laboratories (BIO), Bio-Rad Laboratories (BIO.B), Avantor (AVTR), Bruker (BRKR), Coherent (COHR), Horiba (HRIBF), Accelerate Diagnostics (AXDX), Pacific Biosciences of California (PACB), Quanterix (QTRX), Fluidigm (FLDM), Eyepoint Pharmaceuticals (EYPT) and Harvard Bioscience (HBIO).

Based on aggregate information from My MarketBeat watchlists, some companies that other PerkinElmer investors own include Thermo Fisher Scientific (TMO), Celgene (CELG), Honeywell International (HON), Visa (V), Cisco Systems (CSCO), Illumina (ILMN), NVIDIA (NVDA), CVS Health (CVS), General Electric (GE) and Square (SQ).

PerkinElmer's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Artemis Investment Management LLP (0.25%), Gulf International Bank UK Ltd (0.03%), State of Alaska Department of Revenue (0.02%), Pacer Advisors Inc. (0.01%), Crossmark Global Holdings Inc. (0.01%) and Tributary Capital Management LLC (0.01%). Company insiders that own PerkinElmer stock include Alexis P Michas, Andrew Okun, Daniel R Tereau, Deborah A Butters, Frank Anders Wilson, James Corbett, Joel S Goldberg, Nicholas A Lopardo, Patrick J Sullivan, Peter Barrett, Prahlad R Singh and Robert F Friel. View Institutional Ownership Trends for PerkinElmer.

PKI stock was sold by a variety of institutional investors in the last quarter, including Tributary Capital Management LLC, Artemis Investment Management LLP, State of Alaska Department of Revenue, Gulf International Bank UK Ltd, West Oak Capital LLC and Crossmark Global Holdings Inc.. Company insiders that have sold PerkinElmer company stock in the last year include Alexis P Michas, Andrew Okun, Daniel R Tereau, Deborah A Butters, Joel S Goldberg, Nicholas A Lopardo, Patrick J Sullivan, Peter Barrett and Prahlad R Singh. View Insider Buying and Selling for PerkinElmer.

PKI stock was bought by a variety of institutional investors in the last quarter, including Fox Run Management L.L.C. and Pacer Advisors Inc.. View Insider Buying and Selling for PerkinElmer.

Shares of PKI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PKI stock can currently be purchased for approximately $82.16.

PerkinElmer has a market capitalization of $9.13 billion and generates $2.78 billion in revenue each year. The medical research company earns $237.93 million in net income (profit) each year or $3.61 on an earnings per share basis. PerkinElmer employs 12,500 workers across the globe.View Additional Information About PerkinElmer.

The official website for PerkinElmer is http://www.perkinelmer.com/.

PerkinElmer's mailing address is 940 WINTER STREET, WALTHAM MA, 02451. The medical research company can be reached via phone at 781-663-6900 or via email at [email protected]